Furthermore, the identification of GPR52 selective antagonists through high-throughput screening and studies of the structure-activity connection presents novel possibilities for therapeutic approaches for diseases such as Huntington’s disease (Komatsu, 2021). This evidence concerns the gene GPR52 and juvenile Huntington disease.